BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer
BeyondSpring, Inc. - Ordinary Shares (BYSI)
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beyondspringpharma.com
Company Research
Source: GlobeNewswire
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s novel design for Study 103 was selected for poster presentation at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain. The poster, titled “DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P) / Docetaxel (D) Combination with D Alone in Stage IIIB / IV NSCLC,” was presented on September 9 from 10:15 a.m.-6:15 p.m. local time. Study 103, a Phase 3 global multi-center clinical trial, was undertaken in stage IIIB/IV, EGFR-wild type non-small cell lung cancer (NSCLC) patients [n=554], in 2nd and 3rd line therapy with Docetaxel plus Plinabulin, or Docetaxel in a 1:1 ratio. Patients should have failed a prior line with a platinum-based regimen, and patients who had failed prior PD1/PD-L1 immunotherapy were al
Show less
Read more
Impact Snapshot
Event Time:
BYSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BYSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BYSI alerts
High impacting BeyondSpring, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
BYSI
News
- BeyondSpring Files 2023 Annual Report on Form 20-F [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Files 2023 Annual Report on Form 20-FGlobeNewswire
- BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsGlobeNewswire
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
BYSI
Sec Filings
- 4/29/24 - Form 20-F
- 3/18/24 - Form 6-K
- 2/26/24 - Form 6-K
- BYSI's page on the SEC website